Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Your Daily Pharma Scoop: Dynavax Achieves Major Milestone, GW Pharmaceuticals GWP42006 Fails, Sangamo Signs Deal With Gilead's Kite Unit

2018-02-23 seekingalpha
Today we will discuss Dynavax Technologies (DVAX), which made further progress in its commercialization efforts for Hepatitis B vaccine HEPLISAV-B. (119-0)

DVAX / Dynavax Technologies Corp. FORM 8-K ACIP 2-22-18 (Current Report)

2018-02-22 sec.gov
dvax-8k_20180222.htm     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):   February 21, 2018   Dynavax Technologies Corporation (Exact name of registrant as specified in its charter)   Commission File Number:  001-34207   Delaware    33-0728374 (State or other jurisdiction of incorporation)    (IRS Employer Identification No (39-0)

Biotech Forum Daily Digest For Feb. 22nd

2018-02-22 seekingalpha
After solid gains through most of the day, the biotech sector turned negative late in the day on Fed minutes as did the overall market. (169-0)

Biotech Forum Daily Digest For Feb. 22

2018-02-22 seekingalpha
After solid gains through most of the day, the biotech sector turned negative late in the day on Fed minutes as did the overall market. (169-1)

Dynavax Pops With CDC Recommendation

2018-02-21 247wallst
Shares of Dynavax Technologies Corp. (NASDAQ: DVAX) saw a handy gain early on Wednesday after the company announced that it received a recommendation from the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP). (39-0)

DVAX / Dynavax Technologies Corp. FORM 8-K (Current Report)

2018-02-20 sec.gov
Form 8-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Form 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2018     Dynavax Technologies Corporation (Exact name of registrant as specified in its charter)     Commission File Number: 001-34207   Delaware   33-0728374 (State or other jurisdiction of incorporation)   (IRS Employer Identification No. (39-0)

BRIEF-Dynavax Secures $175 Million In Non-Dilutive Debt Financing

2018-02-20 reuters
* DYNAVAX TECHNOLOGIES - TO RECEIVE $100 MILLION IN A FIRST TRANCHE AND UP TO AN ADDITIONAL $75 MILLION MAY BE BORROWED IN A SECOND TRANCHE AT DYNAVAX‘S OPTION​ (39-0)

DVAX / Dynavax Technologies Corp. / STATE STREET CORP - 3G (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 ANNUAL FILING DYNAVAX TECHNOLOGIES CORPORATION (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 268158201 (CUSIP NUMBER) 12/31/2017 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILED: (X) RULE 13D-1 (B) ( ) RULE 13D-1 (C) ( ) RULE 13D-1 (D) *THE REMAINDER OF THIS COV

DVAX / Dynavax Technologies Corp. / STATE STREET CORP - 3G (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 ANNUAL FILING DYNAVAX TECHNOLOGIES CORPORATION (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 268158201 (CUSIP NUMBER) 12/31/2017 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILED: (X) RULE 13D-1 (B) ( ) RULE 13D-1 (C) ( ) RULE 13D-1 (D) *THE REMAINDER OF THIS COV

DVAX / Dynavax Technologies Corp. / Point72 Asset Management, L.P. - AMENDMENT NO. 1 (Passive Investment)

2018-02-14 sec.gov
240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Dynavax Technologies Corporation (Title of Class of Securities) Common Stock, Par Value $0.

DVAX / Dynavax Technologies Corp. / Point72 Asset Management, L.P. - AMENDMENT NO. 1 (Passive Investment)

2018-02-14 sec.gov
240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Dynavax Technologies Corporation (Title of Class of Securities) Common Stock, Par Value $0.

5 High Risk/High Reward Ways to Play the Rebound | InvestorPlace

2018-02-07 investorplace
Stocks are finding their footing on Wednesday, with the Dow Jones Industrial Average holding with a gain of more than 100 points as of this writing. Meanwhile, the CBOE Volatility Index is falling back to earth and investors are leaving their panic attack. (80-0)

Another February Biotech Catalyst To Watch

2018-02-07 seekingalpha
On Jan. 31, I published an article on three biotech catalysts to watch in February; this article adds another one to the list. (260-13)

Watch These February Biotech Catalysts

2018-01-31 seekingalpha
February has several important catalysts for companies in the biotech; these have the potential to move these stocks significantly in the short term. (157-6)

DVAX / Dynavax Technologies Corp. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-01-29 fintel.io
Dynavax Technologies Corp. (NASDAQ:DVAX) has 127 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 42,786,424 shares. Largest shareholders include BlackRock Inc., State Street Corp, GMT Capital Corp, Vanguard Group Inc, Federated Investors Inc /pa/, D. E. Shaw & Co., Inc., FMR LLC / Fidelity, Polar Capital LLP, Deutsche Bank Ag\, and PointState Capital LP. (88-1)


DVAX : Dynavax Technologies Stock Analysis and Research Report

Dynavax Technologies is a clinical-stage immunotherapy company focused on leveraging the power of the body’s innate and adaptive immune responses through toll-like receptor (“TLR”) stimulation. Dynavax current product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Its lead cancer immunotherapy candidate is SD-101, a C Class CpG TLR9 agonist that was selected for characteristics optimal for treatment of cancer, including high interferon induction. Directly injecting SD-101 into a tumor site optimizes its effect by ensuring proximity to tumor-specific antigens. In animal models, SD-101 demonstrated significant anti-tumor effects at both the injected site and at distant sites. Dynavax is conducting a clinical program intended to assess potential efficacy of SD-101 in a range of tumors and in combination with a range of treatments, including checkpoint inhibitors and...

Click for full article
CUSIP: 268158201